Retrospective Study Evaluating The Current Utilization Of Desvenlafaxine Succinate Sustained-Release (Pristiq) Among Psychiatrists And Primary Care Physicians In The Treatment Of Patients With Major Depressive Disorder

• Other: Pristiq first-line treatment charts
  
  300 charts including patients initiated on Pristiq within the past 6 months as a first-line treatment
• Other: Pristiq second-line treatment charts
  
  800 charts including patients initiated on Pristiq within the past 6 months as a second-line treatment (following first-line treatment with a Serotonin Norepinephrine Reuptake Inhibitor (SNRI) or Selective Serotonin Reuptake Inhibitors (SSRIs)).
• Other: SNRI or SSRI first-line treatment charts
  
  800 charts including patients initiated on a Serotonin Norepinephrine Reuptake Inhibitor (SNRI) or Selective Serotonin Reuptake Inhibitors (SSRIs) (excluding Pristiq) within the past 6 months as a first-line treatment.
• Other: SNRI or SSRI second-line treatment charts
  
  800 charts including patients initiated on a Serotonin Norepinephrine Reuptake Inhibitor (SNRI) or Selective Serotonin Reuptake Inhibitors (SSRIs)(excluding Pristiq) within the past 6 months as a second-line treatment (following the first-line treatment with a SNRI or SSRI).

• Patients initiated on Pristiq as a first line treatment
  
  Intervention: Other: Pristiq first-line treatment charts
• Patients initiated on Pristiq as a 2nd-line treatment
  
  Intervention: Other: Pristiq second-line treatment charts
• Patients initiated on a SNRI or SSRI as a first-line treatment
  
  Intervention: Other: SNRI or SSRI first-line treatment charts
• Patients initiated on a SNRI or SSRI as a 2nd-line treatment
  
  Intervention: Other: SNRI or SSRI second-line treatment charts

Inclusion Criteria:

• Patients must be adult, diagnosed with major depressive disorder and treated with pharmacotherapy.
• Physicians must be either a psychiatrist or a primary care physician, a prescriber of Pristiq, have at least 3 charts representing the 4 identified patient types, have been in clinical practice between 4 and 35 years, primarily office based (50%+), not participated in a research study relating to antidepressants or antidepressant therapy within the past month, not a consultant or have a professional relationship with a pharmaceutical company other than for clinical trials or speaking engagements, and not be employed by of affiliated with an advertising agency, market research company, or pharmaceutical company.

Exclusion Criteria:

• Patients who have not been treated for depression.